WASHINGTON -- Giant cell arteritis (GCA) can be successfully treated with the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq ... oral alternative to tocilizumab (Actemra), the only ...

The company aims to secure its "first mover" position through the approval of Korea's first Actemra biosimilar while also stepping up its efforts to penetrate the global tocilizumab market.

(Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.